טוען...

A novel dual amylin and calcitonin receptor agonist, KBP‐089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference

BACKGROUND AND PURPOSE: Obesity and associated co‐morbidities, such as type 2 diabetes and non‐alcoholic fatty liver disease, are major health challenges. Hence, there is an important need to develop weight loss therapies with the ability to reduce the co‐morbidities. EXPERIMENTAL APPROACH: The effe...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Pharmacol
Main Authors: Gydesen, Sofie, Hjuler, Sara Toftegaard, Freving, Zenia, Andreassen, Kim Vietz, Sonne, Nina, Hellgren, Lars I, Karsdal, Morten Asser, Henriksen, Kim
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345549/
https://ncbi.nlm.nih.gov/pubmed/28109166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13723
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!